Back to All

Biomarker qualification and diagnostic sensitivity in general medicine

18 October, 2018

The FDA has established the Biomarker Qualification Program (BQP) to work with external stakeholders to develop and qualify measurable and reliable biomarkers for a specific use in drug development. Under the BQP process a manufacturer submits evidence to the FDA providing details about the biomarker, the context of use, measurements and unmet need. The FDA accepts the submission when there is potential to address an unmet medical need in drug development. A list of qualified biomarkers can be found on the FDA website.1 The Biomarker Qualification Review is by ‘subject matter experts’ from the CDER.  

The BQP program may need to take a closer look at diagnostic sensitivity following the recent publication of a review of skin biopsy testing where reference values for Chinese-American patients were found to differ from Caucasian Americans.2 This is one of the first investigations into diagnostic sensitivity and the use of worldwide normative values. The findings suggest the need for more stringent standards for skin biopsy test result interpretation because of ethnic differences. 

Diaceutics provide biomarker data analytics and implementation services to support pharmaceutical manufacturers with practical advice, strategies for market access and support for biomarker partnering and qualification. Many developers are interested in multiple biomarker-based companion diagnostics (NGS-based CDx) in general medicine. Our recent work suggests that multiple biomarker tests are being introduced to testing labs across Asia and worldwide, to identify and characterize disease states, to predict outcomes and select treatment. 

Researchers are working on a breadth of areas including asthma, to monitor inflammatory heterogeneity3, prostate cancer to better predict metastasis,and in the prediction of sarcopenia5, the gradual loss of skeletal muscle mass and function with aging.  

Diagnostic and prognostic biomarkers have not been established in every disease area – in Cardiac Sarcoidosis (CS), a Japanese medical team have a theory that a multiple biomarker approach might be best practice to assess risk for cardiac involvement. BNP is reported to be a useful biomarker for cardiac involvement, the cTnl marker indicates fatal arrhythmia and sIL2 and plasma levels of ACE are linked to systemic lesions.6

Another area of multiple biomarker use is in the prediction of renal allograft rejection.  The Chinese group at Jiao Tong University report how biomarkers are urgently required to predict rejection and how a combination of three markers provides a more powerful prediction of rejection than a single-marker.7

There is clearly a need for regulators to address multiple biomarker use and this is an area in which Diaceutics can support manufacturers with Lab Mapping and understanding the Market Access landscape, including country specific insights to drive better laboratory test reimbursement.


  1. [accessed October 10 2018]
  2. Low Sensitivity of Skin Biopsy in Diagnosing Small Fiber Neuropathy in Chinese Americans, Jin et al, J Clin Neuromuscul Dis. 2018 Sep; 20(1): 1–6.
  3. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma, Agache et al, J Allergy Clin Immunol. 2018 Jan;141(1):442-445
  4. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.Zhang et al, Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 54-54.
  5. Prediction of sarcopenia using a combination of multiple serum biomarkers, Kwak et al, Scientific Reportsvolume 8, Article number: 8574 (2018)
  6. [accessed 3 Oct 2018], A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis, Kiko et al, International Heart JournalVolume 59 (2018) Issue 5
  7. Multiple-biomarkers provide powerful prediction of early acute renal allograft rejection by combination of serum fractalkine, IFN-γ and IP-10, Xu et al, [accessed 3 Oct 2018]

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny